NSEAcquisition10 Jul 2026 · 10 Jul 2026, 01:09 pm

Acquisition

Aurobindo Pharma Limited · AUROPHARMA

✦ AI SummaryExpansion

Aurobindo Pharma Limited has informed the Exchange about the incorporation of a new wholly owned step-down subsidiary in Indonesia, PT Auro Pharm Indonesia, to undertake manufacturing operations.

Analysis Scores

Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned stepdown subsidiary in Indonesia.

Attachments (1)

📄

AUROPHARMA_10072026130738_LtrToSEsPTIndonesia10072026.pdf

pdf

Download →
View document text
July 10, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is to inform you that PT Aurogen Pharma Indonesia, a wholly owned stepdown subsidiary of the Company, has incorporated a new wholly owned subsidiary company by the name of PT Auro Pharm Indonesia, in Indonesia. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘Annexure A’. This is for your information and records. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: Annexure A Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 Telangana., India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Annexure ·A Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 a) Name of the target entity, details in brief such Name: PT Auro Pharm Indonesia, Indonesia as size, turnover etc.; Turnover: Not applicable as the company was incorporated on July 1, 2026 and the approval from the authorities for incorporation was received on July 9, 2026. b) Whether the acquisition would fall within PT Auro Pharm Indonesia, Indonesia, is incorporated as related party transaction(s) and whether the a wholly owned step-down subsidiary of the Company promoter / promoter group / group companies and therefore is a related party of the Company. have any interest in the entity being acquired? If Promoters and promoter group of the Company are not yes, nature of interest and details thereof and interested in the transaction whether the same is done at "arms-length"; c) Industry to which the business of the target Pharmaceuticals entity being acquired belongs; d) Objects and effects of acquisition (including The object of incorporation of this wholly owned step- but not limited to, disclosure of reasons for down subsidiary is to undertake manufacturing acquisition of target entity, if its business is operations in Indonesia. outside the main line of business of the listed entity); e) Brief details of any governmental or regulatory No governmental or regulatory approvals required. approvals required for the acquisition. f) Indicative time period for completion of the Not applicable acquisition. g) Nature of consideration - whether cash 100% subscription to the share capital in cash consideration or share swap or any other form and details of the same; h) Cost of acquisition and / or the price at which Initial subscription to the share capital of IDR the shares are acquired; New Subsidiary was 20,000,000,000 divided into 2000 equity shares of IDR, incorporated. 10,000,000 each. i) Percentage of shareholding / control acquired 100% and or number of shares acquired; j) Brief background about the entity acquired in This is a newly incorporated company and therefore the terms of products/line of business acquired, date history of the last 3 years’ turnover is not available. of incorporation, history of last 3 years turnover, country in which the acquired entity has PT Auro Pharm Indonesia was incorporated on July 1st presence and any other significant information 2026 in Indonesia and the approval from the authorities (in brief); for incorporation was received on July 9, 2026. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 Telangana., India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com